The Journal of Clinical and Aesthetic Dermatology

Send us Fan MailDr. Chovatiya reviews generalized pustular psoriasis (GPP) as a distinct, potentially life-threatening inflammatory dermatosis characterized by acute flares and periods of relative quiescence. He highlights the diagnostic challenges in differentiating GPP from plaque psoriasis and other pustular disorders, as well as the central role of interleukin (IL)-36 pathway dysregulation in driving neutrophilic inflammation. He also reviews the use of intravenous therapy for rapid management of active flares and subcutaneous therapy for long-term flare prevention, and how these formulations may be incorporated across the disease course to support both acute control and ongoing GPP management. 

Send us Fan MailDr. Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2026 issue of JCAD.

Send us Fan MailDr. Cohen discusses the treatment of psoriasis in high-impact sites. He outlines how to approach these special considerations and provides treatment options, including the utilization of biologics like risankizumab. He also reviews considerations for unique cases such as nail psoriasis and palmoplantar psoriasis.

Send us Fan MailAhead of National Generalized Pustular Psoriasis (GPP) Awareness Day, Dr. Hawkes gives an overview of the distinct clinical and immunologic features of GPP, emphasizing how this rare, life-threatening disease differs from plaque psoriasis in both presentation and underlying pathophysiology. He highlights the central role of interleukin-36 (IL-36) dysregulation in GPP, explains why therapies developed for plaque psoriasis often do not provide adequate control of the disease, and outlines the rationale for IL-36 receptor inhibition as a targeted treatment strategy. Dr. Hawkes also discusses the practical use of spesolimab for both acute flares and long-term maintenance, including patient selection, dosing approaches, and the rapid clinical responses observed with intravenous therapy.

Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the July 2026 issue of JCAD.

Send us Fan MailFabrizio Galimberti, MD, PhD, reviews the molecular biology behind spesolimab for the treatment of generalized pustular psoriasis (GPP). He highlights the distinction between psoriasis and GPP, while discussing the role that the interleukin-36 pathway plays in inflammation. Dr. Galimberti emphasizes the importance of targeted treatment for flare reduction and improved outcomes in GPP management.

Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2026 issue of JCAD.

Send us Fan MailTina Bhutani, MD, MAS, FAAD, discusses the use of spesolimab, an interleukin-36 receptor blocker, for the treatment of patients with generalized pustular psoriasis. Drawing on real-world patient cases, she highlights its role in rapidly controlling acute flares, improving patient quality of life, and reducing reliance on therapies originally developed for plaque psoriasis.

Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2026 issue of JCAD.

Send us Fan MailBruce Strober, MD, PhD, FAAD, a clinical professor of dermatology at Yale University, discusses his extensive experience in treating patients with psoriasis. He describes his experience treating these patients with risankizumab (Skyrizi), highlighting its efficacy in treating chronic plaque psoriasis and its effectiveness for patients with comorbidities. The therapy has shown rapid improvement in high-impact areas of the body such as the scalp, palms, and soles. Dr. Strober emphasizes risankizumab's effectiveness in patients with psoriatic arthritis and those with low body surface area involvement, often making it a first-line systemic treatment for psoriasis.

Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2026 issue of JCAD.

Send us Fan MailJames Del Rosso, DO, and Joseph Merola, MD, MMSc, discuss recent advances in the treatment of cutaneous lupus erythematosus (CLE). They emphasize the importance of early detection and appropriate laboratory testing to differentiate between cutaneous-only disease and systemic lupus. They highlight the late-breaking phase 2/3 AMETHYST trial (NCT05531565) data for litifilimab, which showed a significant reduction in skin disease activity in patients with CLE by Week 16.

Send us Fan MailJames Del Rosso, DO, Diego Ruiz Dasilva, MD, and Graham Litchman, DO, MS, discuss the clinical efficacy of bimekizumab (Bimzelx) for patients with severe fingernail psoriasis and concomitant psoriatic arthritis (PsA).They highlighted a case of a 56-year-old woman with extensive dystrophic changes across all 10 fingernails and PsA who had been misdiagnosed and treated for years with antifungals and antibiotics without improvement. After initiating bimekizumab, she achieved complete resolution of all nail and joint symptoms within 3 months.In another case, a 63-year-old woman with nail psoriasis and symptomatic PsA experienced near-complete relief of pain, joint stiffness, and loss of hand dexterity within one month of her first dose, with full nail clearance by 3 months. The discussion emphasizes the challenges of diagnosing nail psoriasis, the significant psychosocial burden it imposes, and the potential for accelerated clearance with dual interleukin (IL)-17A and IL-17F inhibition even in the absence of cutaneous psoriatic involvement.Dr. Del Rosso is with JDR Dermatology Research, Las Vegas, Nevada and Touro University Nevada, Henderson, Nevada. Dr. Dasilva is with Forefront Dermatology, Virginia Beach, Virginia and Eastern Virginia Medical School, Norfolk, Virginia. Dr. Litchman is with Vivida Dermatology, Las Vegas, Nevada and Touro University Nevada, Henderson, Nevada.

Send us Fan MailJames Del Rosso, DO, and David Cotter, MD, PhD, discuss the clinical safety and efficacy of nemolizumab for patients with atopic dermatitis (AD). They highlighted a case of an 11-year-old female patient with severe AD who switched from dupilumab (Dupixent) to nemolizumab (Nemluvio). The patient achieved rapid itch reduction and resolution of conjunctivitis and facial erythema. In another case, a 22-year-old female patient with long-standing AD and joint pain switched to nemolizumab, experiencing significant improvement in itch and facial erythema within 2 months. The discussion emphasizes the importance of individualized treatment and the evolving therapeutic landscape for AD.

Send us Fan MailJames Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the March 2026 issue of JCAD.

Send us Fan MailTed Lain, MD, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, shares his extensive experience with deuruxolitinib (Leqselvi) for the treatment of patients with moderate-to-severe alopecia areata. Drawing on 5 years of long-term extension data, Dr. Lain explains that patients generally maintained hair regrowth they achieved early in treatment, with no loss of effect over time. He emphasizes that this durability is crucial, as patients are often most afraid of losing newly regrown hair.

Send us Fan MailJames Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2026 issue of JCAD.

Send us Fan MailJames Del Rosso, DO, and David Cotter, MD, PhD, discuss using gene expression profile testing, such as the AdvanceAD-Tx test, to provide effective treatment for patients with atopic dermatitis. AdvanceAD-Tx allows clinicians to match therapy based on patients’ immune profiles using molecular testing. Drs. Del Rosso and Cotter also review the benefits of using the test not only at baseline, but also throughout treatment in order to tailor their atopic dermatitis therapy and avoid constantly cycling through treatments.

Send us Fan MailAmy McMichael, MD, a clinical professor and chair of the Department of Dermatology at Wake Forest School of Medicine, discusses deuruxolitinib for patients with alopecia areata. She highlights its 8-week efficacy compared to placebo in clinical trials. The medication provided significant improvement in hair regrowth at the 8-mg dose, with minimal adverse events. She emphasized the need to perform standard baseline and intermittent lab tests in patients, similar to other Janus kinase inhibitors.

Send us Fan MailGraham Litchman, DO, MS, a board-certified dermatologist at Vivida Dermatology in Las Vegas, Nevada, discusses a patient case involving a 54-year-old female patient with psoriasis who did not respond well to conventional treatments or systemic steroids. Dr. Lichtman introduced her to risankizumab (Skyrizi), explaining its mechanism of action, adverse events, and dosing schedule. The patient experienced significant improvement by the 3-month mark, with most plaques disappearing. After 1 year of treatment, the patient had only a small area of plaques.

Send us Fan MailJames Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2026 issue of JCAD.

Send us Fan MailDr. Aaron Farberg, a board-certified dermatologist and founder of Bear Dermatology in Dallas, Texas, discusses the evolving treatment landscape for alopecia areata with a focus on Janus kinase inhibitors and how he has used this type of treatment in his practice.

Send us Fan MailDr. Mostaghimi discusses the speed and depth of efficacy of deuruxolitinib for providing hair regrowth in patients with severe alopecia areata.

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the November 2025 issue of JCAD.

Send us Fan MailDrs. Del Rosso and Cotter discuss advances in the molecular understanding of prurigo nodularis, which have enabled the development of targeted pharmaceuticals that treat the root of this condition.

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the October 2025 issue of JCAD.

Send us Fan MailDr. Cotter discusses providing rapid hair regrowth in patients with alopecia areata.

Send us Fan MailDr. Cotter discusses results of an expert consensus panel of the 31-gene expression profile test for patients with Melanoma.

Send us Fan MailDr. Cotter discusses providing effective treatment for patients with alopecia areata  

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the September 2025 issue of JCAD.

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2025 issue of JCAD.

Send us Fan MailDr. Del Rosso discusses advancements in photoprotection formulations, as well as recent FDA approvals that have expanded treatment options for rosacea and psoriasis.

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2025 issue of JCAD.

Send us Fan MailIn this extended cut from JCAD’s recent Journal Review video series, Drs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology.

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2025 issue of JCAD.

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2025 issue of JCAD.

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2025 issue of JCAD.

Send us Fan MailDr. James Del Rosso discusses a recent supplement that reviews insights about the challenges faced by both patients and clinicians in managing vitiligo.

Send us Fan MailDr. Del Rosso discusses potential adverse events that can occur when treating patients with trimethoprim-sulfamethoxazole.

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2025 issue of JCAD.

Send us Fan MailDr. Del Rosso reviews some of the most impactful research developments and drug approvals seen by the dermatology world in 2024.

Send us Fan MailDr. Del Rosso discusses warning signs of serious adverse events related to trimethoprim-sulfamethoxazole prescribed to patients with acne.

Send us Fan MailDr. Song provides helpful clinical tips for treating patients with methotrexate. 

Send us Fan MailDr. Song provides an extensive overview of what’s new and emerging in atopic dermatitis treatment.

Send us Fan MailDr. Del Rosso discusses three exciting new indications for drugs in dermatology and how these approvals will impact clinical practice. 

Send us Fan MailDr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the October 2024 issue of JCAD. 

Send us Fan MailDr. Kircik discusses a recent FDA-approval of an IL-17 inhibitor that has demonstrated to be safe and effective in patients with psoriasis.

Send us Fan MailDr. Del Rosso discusses how to provide the correct treatment for the various presentations of psoriasis along with the impact psoriatic arthritis can have on these patients.

Send us Fan MailDr. Gelfand discusses how to treat patients with psoriasis in terms of cardiovascular risk. He encourages clinicians to educate their patients about these events and the potential side effects they present.

Send us Fan MailDr. Del Rosso discusses ways in which he’s modified his consultation style when speaking to patients with psoriasis who are about to commence treatment with a biologic.